{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T07:27:42Z","timestamp":1725694062993},"publisher-location":"Vienna","reference-count":60,"publisher":"Springer Vienna","isbn-type":[{"type":"print","value":"9783211828915"},{"type":"electronic","value":"9783709174944"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1996]]},"DOI":"10.1007\/978-3-7091-7494-4_7","type":"book-chapter","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T20:54:42Z","timestamp":1343508882000},"page":"75-84","source":"Crossref","is-referenced-by-count":0,"title":["Deprenyl in the treatment of Parkinson\u2019s disease: clinical effects and speculations on mechanism of action"],"prefix":"10.1007","author":[{"given":"C. W.","family":"Olanow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"7_CR1","first-page":"154","volume":"155","author":"J Knoll","year":"1965","unstructured":"Knoll J, Esceri Z, Kelemen K, et al (1965) Phenyliopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155: 154\u2013164","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00426954","volume":"57","author":"JD Elsworth","year":"1978","unstructured":"Elsworth JD, Glover V, Reynolds GP, et al (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the \u201ccheese effect.\u201d Psychopharmacology 57: 33\u201338","journal-title":"Psychopharmacology"},{"key":"7_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/archpsyc.1989.01810010047007","volume":"46","author":"JJ Mann","year":"1989","unstructured":"Mann JJ, Aarons SF, Wilner PJ, et al (1989) A controlled study of the antidepressant efficacy and side-effects of (\u2212)deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46: 45\u201350","journal-title":"Arch Gen Psychiatry"},{"key":"7_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF00431109","volume":"73","author":"N Mendis","year":"1981","unstructured":"Mendis N, Paire CMB, Sandler M, et al (1981) Is the failure of (\u2212)deprenyl, a selective monoamine oxidase B inhibitor, to elevate depression related to freedom from the cheese effect? Psychopharmacology (Berlin) 73: 87\u201390","journal-title":"Psychopharmacology"},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF01246955","volume":"43","author":"J Knoll","year":"1978","unstructured":"Knoll J (1978) The possible mechanisms of action of (\u2212)deprenyl in Parkinson\u2019s disease. J Neural Transm 43: 177\u2013198","journal-title":"J Neural Transm"},{"key":"7_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01253131","volume":"36","author":"W Birkmayer","year":"1975","unstructured":"Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the antiakinetic effect after I-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36: 303\u2013326","journal-title":"J Neural Transm"},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(77)90725-5","volume":"2","author":"AJ Lees","year":"1977","unstructured":"Lees AJ, Kohent LJ, Shaw KM, et al (1977) Deprenyl in Parkinson\u2019s disease. Lancet 2: 791\u2013795","journal-title":"Lancet"},{"key":"7_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1212\/WNL.31.1.19","volume":"31","author":"T Eisler","year":"1981","unstructured":"Eisler T, Teravainen HT, Nelson R, et al (1981) Clinical and biochemical effects of (\u2212)deprenyl in patients with Parkinson\u2019s disease: clinical aspects. Neurology 31: 19\u201323","journal-title":"Neurology"},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1600-0404.1983.tb01524.x","volume":"68","author":"GM Stern","year":"1983","unstructured":"Stern GM, Lees AJ, Hardie RJ, Sandler M (1983) Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson\u2019s disease. Acta Neurol Scand 68: 113\u2013116","journal-title":"Acta Neurol Scand"},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00002826-198802000-00004","volume":"11","author":"LI Golbe","year":"1988","unstructured":"Golbe LI, Lieberman AN, Muenter MD, et al (1988) Deprenyl in the treatment of symptom fluctuations in advanced Parkinson\u2019s disease. Clin Neuropharmol 11: 45\u201355","journal-title":"Clin Neuropharmol"},{"key":"7_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0006-291X(84)91293-2","volume":"120","author":"K Chiba","year":"1984","unstructured":"Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Comm 120: 457\u2013478","journal-title":"Biochem Biophys Res Comm"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0304-3940(87)90543-X","volume":"75","author":"BR Ransom","year":"1987","unstructured":"Ransom BR, Kunis DM, Irwin I, Langston JW (1987) Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett 75: 323\u2013328","journal-title":"Neurosci Lett"},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0014-2999(84)90700-3","volume":"106","author":"G Cohen","year":"1985","unstructured":"Cohen G, Pasik P, Cohen B, et al (1985) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209\u2013210","journal-title":"Eur J Pharmacol"},{"key":"7_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.6332378","volume":"225","author":"JW Langston","year":"1984","unstructured":"Langston JW, Irwin I, Langston EB, Forno LS (1984) Pargyline prevents MPTPinduced parkinsonism in primates. Science 225: 1480\u20131482","journal-title":"Science"},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/311467a0","volume":"311","author":"RE Heikkila","year":"1984","unstructured":"Heikkila RE, Manzino L, Duvoisin RC, Cabbat FS (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase inhibitors. Nature 311: 467\u2013469","journal-title":"Nature"},{"key":"7_CR16","first-page":"32","volume":"40","author":"C Olanow","year":"1990","unstructured":"Olanow CW (1990) Oxidation reactions in Parkinson\u2019s disease. Neurology 40: 32\u201337","journal-title":"Neurology"},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0006-8993(92)91334-B","volume":"593","author":"PF Good","year":"1992","unstructured":"Good PF, Olanow CW, Perl DP (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson\u2019s disease: a LAMMA study. Brain Res 593: 343\u2013346","journal-title":"Brain Res"},{"key":"7_CR18","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1212\/WNL.42.12.2241","volume":"42","author":"P Jenner","year":"1992","unstructured":"Jenner P, Schapira AHV, Marsden CD (1992) New insights into the cause of Parkinson\u2019s disease. Neurology 42: 2241\u20132250","journal-title":"Neurology"},{"key":"7_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/ana.410320703","volume":"32","author":"C Olanow","year":"1992","unstructured":"Olanow CW (1992) Introduction to the free radical hypothesis in Parkinson\u2019s disease. Ann Neurol 32: 2\u20139","journal-title":"Ann Neurol"},{"key":"7_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/0361-9230(92)90118-H","volume":"28","author":"GJ Sengstock","year":"1992","unstructured":"Sengstock GJ, Olanow CW, Dunn AJ, et al (1992) Iron induces degeneration of substantia nigra neurons. Brain Res Bull 28: 645\u2013649","journal-title":"Brain Res Bull"},{"key":"7_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410260518","volume":"26","author":"G Cohen","year":"1989","unstructured":"Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 26: 689\u2013690","journal-title":"Ann Neurol"},{"key":"7_CR22","first-page":"67","volume":"55","author":"J Knoll","year":"1988","unstructured":"Knoll J (1988) Extension of life span of rats by long-term (\u2212)deprenyl treatment. Mt Sinai J Med (NY) 55: 67\u201374","journal-title":"Mt Sinai J Med"},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/BF01245973","volume":"64","author":"W Birkmayer","year":"1985","unstructured":"Birkmayer W, Knoll J, Riederer P, et al (1985) Improvement of life expectancy due to 1-deprenyl addition to Madopar treatment in Parkinson\u2019s disease: a long-term study. J Neural Transm 64: 113\u2013127","journal-title":"J Neural Transm"},{"key":"7_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1126\/science.2502843","volume":"245","author":"JW Tetrud","year":"1989","unstructured":"Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson\u2019s disease. Science 245: 519\u2013522","journal-title":"Science"},{"key":"7_CR25","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","volume":"46","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group (1989) DATATOP: a multicenter controlled clinical trial in early Parkinson\u2019s disease. Arch Neurol 46: 1052\u20131060","journal-title":"Arch Neurol"},{"key":"7_CR26","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","volume":"321","author":"Parkinsons Study Group","year":"1989","unstructured":"Parkinson\u2019s Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson\u2019s disease. NEJM 321: 1364\u20131371","journal-title":"NEJM"},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1056\/NEJM199301213280305","volume":"328","author":"Parkinsons Study Group","year":"1993","unstructured":"Parkinson\u2019s Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson\u2019s disease. NEJM 328: 176\u2013183","journal-title":"NEJM"},{"key":"7_CR28","first-page":"157","volume":"128","author":"MD Yahr","year":"1989","unstructured":"Yahr MD, Elizan TS, Moros D (1989) Selegiline in the treatment of Parkinson\u2019s disease\u2014long term experience. Acta Neurol Scand 128: 157\u2013161","journal-title":"Selegiline in the treatment of Parkinson\u2019s disease\u2014long term experience"},{"key":"7_CR29","first-page":"13","volume":"42","author":"CW Olanow","year":"1991","unstructured":"Olanow CW, Calne D (1991) Does selegiline monotherapy in Parkinson\u2019s disease act by symptomatic or protective mechanisms? Neurology 42: 13\u201326","journal-title":"Neurology"},{"key":"7_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.410380512","volume":"38","author":"CW Olanow","year":"1995","unstructured":"Olanow CW, Hauser RA, Gauger L, et al (1995) A longtitudinal, double-blind, controlled study of the effect of deprenyl and levodopa on the progression of signs and symptoms of Parkinson\u2019s disease. Ann Neurol 38: 771\u2013777","journal-title":"Ann Neurol"},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1471-4159.1987.tb02895.x","volume":"49","author":"CD Arnett","year":"1987","unstructured":"Arnett CD, Fowler JS, MacGregor RR, et al (1987) Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L(IIC) deprenyl. J Neurochem 49: 522\u2013527","journal-title":"J Neurochem"},{"key":"7_CR32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1212\/WNL.44.1.200-a","volume":"44","author":"RA Hauser","year":"1994","unstructured":"Hauser RA, Olanow CW, Koller WC (1994) Time course of wash-out of symptomatic medication in Parkinson\u2019s disease. Neurology 44: 259","journal-title":"Neurology"},{"key":"7_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/ana.410320614","volume":"32","author":"M Schulzer","year":"1992","unstructured":"Schulzer M, Mark E, Calne DB (1992) The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 32: 795\u2013798","journal-title":"Ann Neurol"},{"key":"7_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ana.410370117","volume":"37","author":"T Brannan","year":"1995","unstructured":"Brannan T, Yahr MD (1995) Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson\u2019s disease. Ann Neurol 37: 95\u201398","journal-title":"Ann Neurol"},{"key":"7_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bmj.307.6902.469","volume":"307","author":"Parkinson Disease Research Group in the United Kingdom","year":"1993","unstructured":"Parkinson Disease Research Group in the United Kingdom (1993) Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson\u2019s disease: three year interim report. BMJ 307: 469\u2013472","journal-title":"BMJ"},{"key":"7_CR36","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/archneur.1989.00520480017012","volume":"46","author":"TS Elizan","year":"1989","unstructured":"Elizan TS, Yahr MD, Moros DA, et al (1989) Selegiline use to prevent progression of Parkinson\u2019s disease. Experience in 22 de novo patients. Arch Neurol 46: 1275\u20131279","journal-title":"Arch Neurol"},{"key":"7_CR37","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1001\/archneur.1989.00520480022013","volume":"46","author":"TS Elizan","year":"1989","unstructured":"Elizan TS, Yahr MD, Moros DA, et al (1989) Selegiline as an adjunct to conventional levodopa therapy in Parkinson\u2019s disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Arch Neruol 46: 1280\u20131283","journal-title":"Arch Neruol"},{"key":"7_CR38","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ana.410330404","volume":"33","author":"Parkinson study group","year":"1993","unstructured":"Parkinson study group (1993) A controlled clinical trial of lazabemide (ROI9-6327) in untreated Parkinson\u2019s disease. Ann Neurol 33: 350\u2013356","journal-title":"Ann Neurol"},{"key":"7_CR39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archneur.1994.00540160036006","volume":"51","author":"Parkinson Study Group","year":"1994","unstructured":"Parkinson Study Group (1994) A controlled trial of Lazabemide (R019-6327) in levodopa-treated Parkinson\u2019s disease. Arch Neurol 51: 342\u2013347","journal-title":"Arch Neurol"},{"key":"7_CR40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0014-2999(88)90308-1","volume":"146","author":"MV Kindt","year":"1988","unstructured":"Kindt MV, Youngster SK, Sonsalla PK, et al (1988) Role for the monoamine oxidase A (MAO-A) in the bioactivation and nigral striatal dopaminergic neurotoxicity of the MPTP analog 2\u2019ME-MPTP. Eur J Pharmacol 146: 313\u2013318","journal-title":"Eur J Pharmacol"},{"key":"7_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/265080a0","volume":"265","author":"V Glover","year":"1977","unstructured":"Glover V, Sandler M, Owen F, Riley G (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265: 80\u201381","journal-title":"Nature"},{"key":"7_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.3875898","volume":"230","author":"KN Westlund","year":"1985","unstructured":"Westlund KN, Denney RM, Kochersperger LM, et al (1985) Distinct monoamine oxidase A and B populations in the primate brain. Science 230: 181\u2013183","journal-title":"Science"},{"key":"7_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/archneur.1995.00540270025015","volume":"52","author":"Parkinsons Study Group","year":"1995","unstructured":"Parkinson\u2019s Study Group (1995) Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson\u2019s disease. Arch Neurol 52: 237\u2013245","journal-title":"Arch Neurol"},{"key":"7_CR44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mds.870080305","volume":"8","author":"B Pardo","year":"1993","unstructured":"Pardo B, Mena MA, Fahn S, DeYebenes JG (1993) Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 8: 278\u2013284","journal-title":"Mov Disord"},{"key":"7_CR45","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/jnr.490300410","volume":"30","author":"WG Tatton","year":"1991","unstructured":"Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666\u2013677","journal-title":"J Neurosci Res"},{"key":"7_CR46","first-page":"202","volume-title":"Neurodegeneration and prospects for neuroprotection in Parkinson\u2019s disease","author":"WG Tatton","year":"1996","unstructured":"Tatton WG, Ju WYH, Wadia J, Tatton NA (1996) Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow CW, Jenner P, Youim MHB (eds) Neurodegeneration and prospects for neuroprotection in Parkinson\u2019s disease. Academic Press, London, pp 202\u2013220"},{"key":"7_CR47","doi-asserted-by":"crossref","unstructured":"Finnegan KT, Skratt JJ, Irwin I, et al (1990) Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184","DOI":"10.1016\/0014-2999(90)90672-S"},{"key":"7_CR48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0014-2999(93)90181-G","volume":"243","author":"RM Wu","year":"1993","unstructured":"Wu RM, Chieuh CC, Pert A, Murphy DL (1993) Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 243: 241\u2013247","journal-title":"Eur J Pharmacol"},{"key":"7_CR49","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/j.1471-4159.1985.tb10556.x","volume":"45","author":"C Mytilineou","year":"1985","unstructured":"Mytilineou C, Cohen G (1985) Deprenyl protects dopamine neurons from the neurotoxic effect of l-methyl-4-phenyl-pyridinium ion. J Neurochem 45: 1951\u20131953","journal-title":"J Neurochem"},{"key":"7_CR50","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.8235659","volume":"262","author":"DJ Kane","year":"1993","unstructured":"Kane DJ, Sarafian TA, Anton R, Hahn H, Gralia EB, Valentine JS, Ord T, Bresdesen DE (1993) Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262: 1274\u20131276","journal-title":"Science"},{"key":"7_CR51","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/j.1471-4159.1993.tb03275.x","volume":"60","author":"SP Mah","year":"1993","unstructured":"Mah SP, Zhong LT, Liu Y, Roghani A, Edwards RH, Bredesen DE (1993) The protooncogene bcl-2 inhibits apoptosis in PC12 cells. J Neurochem 60: 1183\u20131186","journal-title":"J Neurochem"},{"key":"7_CR52","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/0306-4522(94)90566-5","volume":"63","author":"G Walkinshaw","year":"1994","unstructured":"Walkinshaw G, Waters CM (1994) Neurotoxin induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience 63: 975\u2013987","journal-title":"Neuroscience"},{"key":"7_CR53","doi-asserted-by":"crossref","unstructured":"Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA; implications for the treatment of Parkinson\u2019s disease. J Clin Inv 2458\u20132464","DOI":"10.1172\/JCI117946"},{"key":"7_CR54","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/0304-3940(94)90258-5","volume":"170","author":"I Ziv","year":"1994","unstructured":"Ziv I, Melamed E, Nardi N, Luria D, Achiron A, Offen D, Barzilai A (1994) Dopamine induces apoptosis-like cell death in cultured chick sympathetic. Neurosci Lett 170: 136\u2013140","journal-title":"Neurosci Lett"},{"key":"7_CR55","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/j.1471-4159.1993.tb13642.x","volume":"61","author":"C Mytilineou","year":"1993","unstructured":"Mytilineou C, Han S-K, Cohen G (1993) Toxic and protective effects of I-DOPA on mesencephalic cell cultures. J Neurochem 61: 1470\u20131478","journal-title":"J Neurochem"},{"key":"7_CR56","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1046\/j.1471-4159.1996.66020501.x","volume":"66","author":"S-K Han","year":"1996","unstructured":"Han S-K, Mytilineou C, Cohen G (1996) L-DOPA upregulates glutathione (GSH) and protects mesencephalic cultures against oxidative stress. J Neurochem 66: 501\u2013510","journal-title":"J Neurochem"},{"key":"7_CR57","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/350230a0","volume":"350","author":"C Hyman","year":"1991","unstructured":"Hyman C, Hofer M, Barde YA, et al (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350: 230\u2013233","journal-title":"Nature"},{"key":"7_CR58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1471-4159.1992.tb08880.x","volume":"59","author":"MB Spina","year":"1991","unstructured":"Spina MB, Squinto Sp, Miller J, et al (1991) BDNF protects dopamine neurons against 6-OHDA and MPP+: involvement of the glutathione system. J Neurochem 59: 99\u2013106","journal-title":"J Neurochem"},{"key":"7_CR59","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1046\/j.1471-4159.1994.63041572.x","volume":"63","author":"WG Tatton","year":"1994","unstructured":"Tatton WG, Ju WYL, Holland DP, et al (1994) (\u2212)-Deprenyl reduces PC12 cell apoptosis by inducing new protein sythesis. J Neurochem 63: 1572\u20131575","journal-title":"J Neurochem"},{"key":"7_CR60","doi-asserted-by":"crossref","unstructured":"Mytilineou C, Radcliffe P, Leonardi EK, et al (1996) L-Deprenyl protects mesencephalic dopamine neurons from glutamate-receptor-mediated toxicity. J Neurochem (in press)","DOI":"10.1046\/j.1471-4159.1997.68010033.x"}],"container-title":["Deprenyl \u2014 Past and Future"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-7091-7494-4_7.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T17:54:38Z","timestamp":1714240478000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-7091-7494-4_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996]]},"ISBN":["9783211828915","9783709174944"],"references-count":60,"URL":"https:\/\/doi.org\/10.1007\/978-3-7091-7494-4_7","relation":{},"subject":[],"published":{"date-parts":[[1996]]}}}